Business of Medicine
Latest News
CMS Announces End to Cyberattack Relief Program
Payments from the Accelerated and Advance Payment program will close for application in July.
Commentary
Is This Journal Legit? Predatory Publishers
Physicians discuss various publishing models, and what journal characteristics to look out for as predatory.
Feature
Oncology Mergers Are on the Rise. How Can Independent Practices Survive?
The number of community practices acquired by hospitals nearly tripled from 2010 to 2020, according to a report from COA.
Latest News
Medicare Advantage Plans Not Always Advantageous
Enrollees who switched from traditional Medicare to Medicare Advantage saw little savings and reduced accessibility of specialty care.
Latest News
See the Medical World Through Neurodivergent Doctors’ Eyes
Neurodivergent doctors are judged by their response to stressors that put them at a disadvantage rather than their capabilities under more...
Latest News
US Hospitals Prone to Cyberattacks Like One That Impacted Patient Care at Ascension, Experts Say
Cyberattacks led to delays in lab results, medication errors, and other system issues that could have cost lives.
Managing Your Practice
Should You Offer Medical Credit Cards?
Traditionally, these cards were used to help cover procedures insurance didn't cover -- such as cosmetic procedures -- but over the years, they...
Feature
Doctors Endorsing Products on X May Not Disclose Company Ties
Researchers review posts by physicians on X, looking for key words that might indicate that the posts were intended as endorsements of a product...
Commentary
DEA Training Mandate: 8 Hours of My Life I’d Like Back
Dr. Walton-Shirley describes changes needed to renew DEA licenses so that others who prescribe very few narcotics do not have to spend so much...
Latest News
AMA Wrestles With AI But Acts on Prior Authorization, Other Concerns
One resolution would establish “augmented intelligence” as the preferred term for AI, reflecting the desired role of these tools in supporting —...
From the Journals
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D Plans
This narrow coverage limits the cost-saving potential of these biosimilar competitors, the authors of a new study said.